Indoco Remedies ka Share: **₹110 Crore** mein eye care business becha, ab debt kam hoga!

BANKINGFINANCE
Whalesbook Logo
AuthorAnanya Iyer|Published at:
Indoco Remedies ka Share: **₹110 Crore** mein eye care business becha, ab debt kam hoga!
Overview

Indoco Remedies ne apna eye care business Sunways (India) Private Limited ko **₹110 crore** mein bech diya hai. Isse company ka revenue ka sirf **3.2%** wala chhota sa hissa nikal jayega, taki wo formulations aur API manufacturing jaise bade growth areas par focus kar sake. Ye deal Indoco ki financial stability improve karne ke liye hai, jo filhaal high interest costs aur net losses se pareshan hai.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Capital Allocation Par Naya Focus

Indoco Remedies ne apna ophthalmic business Sunways (India) Private Limited ko ₹110 crore mein bech diya hai. Ye ek strategic move hai jisme company ne ek chhota sa segment (jo last fiscal year mein Indoco ke standalone revenue ka sirf 3.2% tha) se bahar nikalne ka faisla kiya hai. Is deal se mile paise ko ab Indoco apne core strengths, yaani Active Pharmaceutical Ingredients (APIs) aur complex generic formulations par invest karegi.

Financial Pressure Ko Kam Karne Ki Koshish

Ye deal company par chal rahe financial pressure ko kam karne ke liye ek bada kadam hai. Indoco ne FY26 ke fourth quarter mein interest expenses mein ₹45.92 crore ka sharp increase report kiya tha, jo ab tak ka sabse high hai. Is wajah se interest coverage ratio 1.0x se neeche chala gaya tha. Iska natija ye hua ki FY26 mein company ko ₹98.70 crore ka consolidated net loss hua, bhale hi overall revenue badha ho. Sunways, jisko private equity ka support hai, is acquisition ko apne ophthalmic business ko expand karne ka ek accha mauka maan rahi hai.

Abhi Bhi Kuch Challenges Hain

Halanki ye deal immediate cash laane mein madad karegi, Indoco ki financial structure abhi bhi ek concern bani hui hai. Company ka debt-to-EBITDA ratio 3.78x hai, jo batata hai ki abhi aur financial adjustments ki zaroorat hai. High finance costs ne Indoco ki profitability ko kaafi affect kiya hai, jisse company interest rate changes ke liye vulnerable ho gayi hai. Investors ko yahan thoda caution dikhane ki zaroorat hai, kyunki ye divestment sirf short-term relief de sakti hai aur company ki underlying operational cost issues ko permanently solve nahi kar sakti.

Aage Kya?

Is strategy ki success Indoco ki ability par depend karegi ki wo kitne effective tareeke se is proceeds ko apne USFDA-compliant facilities aur API pipeline mein reinvest kar sakti hai. Market ab dekh rahi hai ki kya ye sale assets ko monetize karne ke ek sustained effort ki shuruat hai ya sirf immediate debt reduction ka ek step hai. Company ki future profitability is baat par nirbhar karegi ki wo revenue growth ko actual profits mein kaise badal pati hai.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.